弥漫大B细胞淋巴瘤患者临床特征及预后分析

赵洁, 姜言, 郝思国

Clinical characteristics and prognosis of patients with diffuse large B-cell lymphoma

ZHAO Jie, JIANG Yan, HAO Siguo

图1 ASCT及利妥昔单抗维持治疗的DLBCL患者的生存曲线与生存分析 Note： A. OS curve of relapsed/refractory DLBCL patients with ASCT (Log-rank P=0.019). B. OS curve of ASCT or rituximab maintenance therapy in patients in the high-risk group with CR who had achieved interim assessment (ASCT vs no consolidation therapy, Log-rank P=0.361; rituximab maintenance vs no consolidation therapy, Log-rank P=0.546. There was no significant difference among the three groups, P=0.511).

Fig1 Survival curves and survival analysis of patients with ASCT or rituximab maintenance therapy